MiteshJBoradMD

Oncology • Scottsdale, AZ

Assistant Professor of Medicine Mayo Clinic

Join to view full profile

Dr. Borad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borad's full profile

Already have an account?

Office
13400 E Shea Blvd
Scottsdale, AZ 85259
Phone+1 480-301-8000

Education & Training

Tulane UniversityFellowship, Hematology and Medical Oncology, 2003 - 2005
Cedars-Sinai Medical CenterResidency, Internal Medicine, 2000 - 2003
Rutgers New Jersey Medical SchoolClass of 2000

Certifications & Licensure

CA State Medical License 2001 - Present
AZ State Medical License 2005 - 2027
LA State Medical License 2003 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors Start of enrollment: 2010 Jul 01
Completed
Phase 1
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients Start of enrollment: 2011 Nov 01
Terminated
Phase 2
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery Start of enrollment: 2012 May 01
Completed
Phase 1
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors Start of enrollment: 2012 Aug 03
ACTIVE_NOT_RECRUITING
PHASE1
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Start of enrollment: 2013 Apr 01
Terminated
Phase 1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Start of enrollment: 2014 Jul 23
Terminated
Phase 2
Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors Start of enrollment: 2015 Feb 18
Terminated
Phase 1
Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions Start of enrollment: 2014 Dec 01
Completed
Phase 2
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Start of enrollment: 2016 Jan 01
Completed
Early Phase 1
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Start of enrollment: 2017 May 25
Terminated
Phase 1
A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma Start of enrollment: 2018 Mar 07
Completed
Phase 2
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Start of enrollment: 2018 Sep 26
Active, not recruiting
Phase 2
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Start of enrollment: 2019 Sep 20
Terminated
Phase 2, Phase 3
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Start of enrollment: 2019 Oct 18
Completed
Phase 2
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma Start of enrollment: 2021 Oct 20
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma.
Chelsae R Watters, Oumar Barro, Musa Gabere, Mia Y Masuda, Natalie M Elliott
Molecular Therapy. Oncology. 2025-03-20
Transforming Hepatocellular Carcinoma Treatment in Lower Income Countries.
Channa R Jayasekera, Chrishanthi Rajasooriyar, Clayton Richards, Sanjeev Arora, Mitesh J Borad
Mayo Clinic Proceedings. 2025-03-07
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
Do-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, Carlos Rojas, Chih-Hung Hsu
Hepatology. 2025-03-01

Journal Articles

Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma
Mohamad Bassam Sonbol, Amit Mahipal, Zhaohui Jin, Kabir Mody, Mitesh J Borad, Daniel H Ahn, Tanios Bekaii-Saab, JAMA Oncology
E6201, an Intravenous MEK1 Inhibitor, Achieves an Exceptional Response in BRAF V600E-Mutated Metastatic Malignant Melanoma with Brain Metastases
Mitesh J Borad, Raoul Tibes, Michael S Gordon, Ronald L Korn, Investigational New Drugs
Chromoanasynthesis Is a Common Mechanism That Leads to ERBB2 Amplifications in a Cohort of Early Stage HER2+ Breast Cancer Samples
Katherine B Geiersbach, Mitesh J Borad, Sarah A McLaughlin, BioMed Central

Lectures

A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) chol...
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
Clinical Hematology and Oncology 2013: The 10th Annual Mayo Board Review
Mayo School of Continuous Professional Development, Scottsdale, Arizona - 1/18/2013